Molecule News and Research

RSS

Lab-on-Bead technology helps researchers cut years from drug development

New research accepted by the Journal of Molecular Recognition confirms that a revolutionary technology developed at Wake Forest University will slash years off the time it takes to develop drugs - bringing vital new treatments to patients much more quickly.

16 Jul 2010

Human impact on health of soil, and impact of unhealthy soil on society are intertwined, says LSU researcher

It may sound counterintuitive, but LSU Associate Professor of Chemistry Robert Cook has made a career out of studying the ways organic materials found in the environment, including soils, can either get dirty or stay clean. In fact, the National Science Foundation, or NSF, was so impressed with his efforts that the funding institute awarded Cook one of its most prestigious awards - the NSF CAREER award.

16 Jul 2010

LLC to provide contract drug development services

LyoTechnica, LLC has announced that it has been established to provide contract drug development services for injectable pharmaceuticals. The company and its affiliates bring over 80 years of combined experience in lyophilization and liquid dosage form development as well as over 100 years experience in commercial scale manufacturing of parenteral drugs. The company offers analytical and formulation development, manufacturing of sterile stability batches and stability testing services.

16 Jul 2010

New findings on macrophage activation can facilitate development of early diagnosis tools

Immune system cells called macrophages spring into action to surround and destroy threats such as viruses or cancer cells. But sometimes the would-be protective response leads to persistent inflammation, which, in turn, can cause disease.Scientists don't know exactly how macrophages cross the line from being good cops to bad cops, but researchers at the University of Florida recently unearthed several clues about the mechanisms involved. Through the lens of two inflammation-related diseases, HIV and rheumatoid arthritis, they identified changes in specific proteins linked to the action of macrophages, white blood cells that are key to the body's natural defenses.

16 Jul 2010

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

NovaBay Pharmaceuticals, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office on a patent application for a broad portfolio of anti-infective compounds, including NVC-612. The patent will broaden protection for NovaBay's first-in-class Aganocide family of compounds, which are designed to fight infections without causing drug resistance.

15 Jul 2010

NIH awards MacroGenics $9.8 million grant for three projects

MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants representing total funding of $9.8 million.

15 Jul 2010

PharmSource ranks Patheon as top global contract development and manufacturing organization

Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that it has been ranked as a top global contract development and manufacturing organization. PharmSource(R), a respected independent pharmaceutical research organization, recently published a study looking at the number of FDA new drug approvals (NDAs and BLAs) which were outsourced by sponsor companies and subsequently launched.

15 Jul 2010

Activities of TAT fully consolidated into Geron

Geron Corporation today announced that the activities of TA Therapeutics, its joint venture with Hong Kong University of Science and Technology, are being fully consolidated into Geron.

15 Jul 2010

Watson Pharmaceuticals signs exclusive, worldwide licensing agreement with Itero Biopharmaceuticals

Watson Pharmaceuticals, Inc. today announced an exclusive, worldwide licensing agreement with Itero Biopharmaceuticals, Inc., a venture-backed specialty biopharmaceutical company, to develop and commercialize Itero's Recombinant Follicle Stimulating Hormone. The product is currently in preclinical development as a biosimilar molecule for the treatment of female infertility.

15 Jul 2010

New drug launches for HCV in the Philippines to increase market earned revenues to $4.5 billion by 2017

Efforts to raise disease awareness in the Philippines have increased the number of cases and patient pool available for hepatitis C treatment. Screening and detection efforts by the Red Cross as well as growing awareness in the Philippines have been largely responsible for the rise in the number of diagnosed cases. These campaigns have encouraged people, mostly from the urban areas, to opt for physical examinations that enable the detection of hepatitis C.

15 Jul 2010

Pre-clinical study results of EVP-0015962 presented at AAICAD 2010

EnVivo Pharmaceuticals today announced at the Alzheimer's Association 2010 International Conference on Alzheimer's Disease results from its proprietary gamma-secretase modulator pre-clinical study. In a transgenic mouse model, EnVivo's EVP-0015962 reduced amyloid plaque buildup which is believed to be a cause of Alzheimer's disease, reversed behavioral deficits and reduced brain inflammation associated with Alzheimer's disease.

15 Jul 2010

New research focuses on calcium channels in lysosome membrane

In cells, as in cities, disposing of garbage and recycling anything that can be reused is an essential service. In both city and cell, health problems can arise when the process breaks down.

15 Jul 2010

Trevena completes $35M Series B financing

Trevena, Inc., the leader in discovery and development of G-protein coupled receptor biased ligands, announced today that it has completed a $35 million Series B financing. Existing investors Polaris Venture Partners and New Enterprise Associates led the round, with all other existing Trevena investors - Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company - also participating in the financing.

14 Jul 2010

Pacific Biosciences completes $109M Series F financing round

Pacific Biosciences, a private company developing a disruptive technology platform for real-time detection of biological events at single molecule resolution, today announced it has completed a Series F round of financing in the amount of $109 million.

14 Jul 2010

Study: Disruption of genes that control circadian rhythms may lead to diabetes

Disruption of two genes that control circadian rhythms can lead to diabetes, a researcher at UT Southwestern Medical Center has found in an animal study. Mice with defective copies of the genes, called CLOCK and BMAL1, develop abnormalities in pancreatic cells that eventually render the cells unable to release sufficient amounts of insulin.

14 Jul 2010

LLS awards two new grants through prestigious Marshall A. Lichtman SCOR research initiative

The Leukemia & Lymphoma Society today announced it has awarded two new grants through its prestigious Marshall A. Lichtman Specialized Center of Research research initiative, bringing the program's total funding to $210.5 million since its inception in 2000.

13 Jul 2010

Examination of cellular construction of motion detector in brain of fly

What would be the point of holding a soccer world championship if we couldn't distinguish the ball from its background? Simply unthinkable! But then again, wouldn't it be fantastic if your favourite team's striker could see the movements of the ball in slow motion! Unfortunately, this advantage only belongs to flies.

13 Jul 2010

MRC Technology, Genentech sign licensing agreement

MRC Technology (UK) announced today that it has entered into an agreement with Genentech, Inc., a wholly owned member of the Roche Group for an exclusive licence to a series of small molecule drug candidates for the potential treatment of neurological disease.

12 Jul 2010

Discovery of antibodies that kill more than 90% of HIV viruses gives new hope for vaccine

"An effective vaccine against the AIDS virus may have moved one step closer to reality, researchers said Thursday," the Los Angeles Times reports. "Federal researchers have identified a pair of naturally occurring antibodies that are able to kill more than 90% of all strains of the AIDS virus, a finding they say could lead to the development of new treatments for HIV infections and to the production of the first successful vaccine against the virus" (Maugh, 7/9).

12 Jul 2010

Subtle mutation affecting epigenome may lead to inherited form of mental retardation: Researchers

A subtle mutation affecting the epigenome –- a set of dynamic factors that influence gene activity -- may lead to an inherited form of mental retardation that affects boys, find researchers at Children's Hospital Boston. The disorder, which also involves cleft lip or cleft palate, appears to hinge on an enzyme working in a biological pathway that may offer several potential drug targets.

12 Jul 2010

Molecule News and Research

Lab-on-Bead technology helps researchers cut years from drug development

Human impact on health of soil, and impact of unhealthy soil on society are intertwined, says LSU researcher

LLC to provide contract drug development services

New findings on macrophage activation can facilitate development of early diagnosis tools

NovaBay Pharmaceuticals issued Notice of Allowance for broad portfolio of anti-infective compounds

NIH awards MacroGenics $9.8 million grant for three projects

PharmSource ranks Patheon as top global contract development and manufacturing organization

Activities of TAT fully consolidated into Geron

Watson Pharmaceuticals signs exclusive, worldwide licensing agreement with Itero Biopharmaceuticals

New drug launches for HCV in the Philippines to increase market earned revenues to $4.5 billion by 2017

Pre-clinical study results of EVP-0015962 presented at AAICAD 2010

New research focuses on calcium channels in lysosome membrane

Trevena completes $35M Series B financing

Pacific Biosciences completes $109M Series F financing round

Study: Disruption of genes that control circadian rhythms may lead to diabetes

LLS awards two new grants through prestigious Marshall A. Lichtman SCOR research initiative

Examination of cellular construction of motion detector in brain of fly

MRC Technology, Genentech sign licensing agreement

Discovery of antibodies that kill more than 90% of HIV viruses gives new hope for vaccine

Subtle mutation affecting epigenome may lead to inherited form of mental retardation: Researchers

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News